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INTRODUCTION 
The reported LD50 for technical grade bromethalin 
ranges from 1.8 mg/kg in the cat, 4.7 mg/kg in the dog, and 
13 mg/kg in rabbits, and up to >1000 mg/kg in guinea pigs 
(VanLier and Ottosen 1981, VanLier and Cherry 1988). 
Mitochondrial electron transport studies using purified rat 
brain and liver mitochondria have been performed, and have 
established that bromethalin is an effective uncoupler of 
oxidative phosphorylation (VanLier and Ottosen 1981, Cherry 
et al. 1982, VanLier and Cherry 1988). Mitochondrial 
oxidative phosphorylation is the major mechanism for 
production of ATP in the brain. Uncoupling of this reaction 
in bromethalin-poisoned animals may result in a lack of 
adequate ATP formation and diminished Na+ - K+ ion 
channel pump activity. We are currently investigating 
alternate mechanisms of action for bromethalin toxicosis in the 
rat. Regardless of mechanism of action, cerebral edema and 
elevated cerebrospinal fluid pressure (CSFP) develops. 
Microscopic examination of neurologic tissues (brain and 
spinal cord) from lethally dosed animals revealed diffuse 
spongy degeneration of the white matter and intramyelinic 
edema (VanLier and Cherry 1988, Dorman et al. 1990). 
The toxic syndrome induced by bromethalin is dose-
dependent. Rats given high oral doses (in excess of the 
LD50) of bromethalin develop an acute toxic syndrome 
characterized by severe muscle tremors, hyperexcitability, and 
seizures (VanLier and Cherry 1988). Death may result within 
8 to 24 hours due to apparent respiratory arrest. Following 
the ingestion of lower oral doses (less than an LD50) the 
onset of clinical signs may be delayed (e.g., 24 to 86 hours). 
This second syndrome is characterized in the rat by the 
development of hindlimb weakness, paralysis, prostration, and 
lethargy (VanLier and Cherry 1988). 
Bromethalin is N-demethylated by the hepatic mixed 
function oxidase (mfo) system to its desmethylbromethalin 
metabolite (Fig. 1). Desmethylbromethalin has been 
demonstrated to be a 10- to 1000-fold more potent uncoupler 
of oxidative phosphorylation than is bromethalin (VanLier and 
Cherry 1988). The apparent lack of toxicity of bromethalin 
observed in guinea pigs may be partially explained by their 
relative deficiency in N-demethylase activity. Production of 
desmethylbromethalin, therefore, appears to be involved in the 
production of the toxic syndrome. The use of an antimetabo-
lite which inhibits the conversion of bromethalin to its 
desmethylbromethalin metabolite may represent another 
potential treatment for bromethalin toxicosis. 
An ideal antimetabolite of bromethalin should have the 
following characteristics: a) it should be metabolized by the 
same microsomal isozymes which N-demethylates bromethalin, 
b) it should be low in toxicity, and c) it should be readily 
available. Based upon these considerations aminophylline 
(theophylline ethylenediamine) was selected as a potential 
bromethalin antimetabolite. Theophylline is a 1,3-dimethylated 
xanthine which is similar in structure to caffeine and 
theobromine (Fig. 2). Theophylline is metabolized by two N-
demethylations and an 8-hydroxylation to form 1-
methylxanthine, 3-methylxanthine, and 1,3-dimethyluric acid 
(Lohman and Meich 1976).  Studies of the in vitro 
metabolism of theophylline by human microsomes indicate 
that two distinct cytochrome P-450 isozymes are involved in 
these reactions (Robson et al. 1988). Theophylline is 
commonly used as a bronchodilator and is readily available. 
Theophylline is of moderate oral toxicity with an acute oral 
LD50 of 300 mg/kg in the dog and 700 mg/kg in the cat. 
 
 
 
Figure 1.   Metabolism of bromethalin. 
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The purpose of this report is to further define the toxicity 
of bromethalin-based rodenticides in nontarget species by 
presenting the clinical signs associated with spontaneous 
bromethalin rodenticide ingestion. Furthermore, we also 
examined the efficacy of aminophylline administration in the 
treatment of lethal bromethalin toxicosis in the rat. 
 
Figure 2.   Structure of theophylline. 
MATERIALS AND METHODS    
A.  Retrospective Epidemiologic Study 
Epidemiologic and clinical information was compiled from 
the Illinois Animal Poison Information Center (IAPIC) case 
record database. The IAPIC is located at the University of 
Illinois and receives calls from throughout the United States 
and Canada. The IAPIC protocol collects the following 
information whenever possible: the animal’s age, sex, breed, 
species, number at risk, number exposed, the number of 
animals affected, the amount of product involved, source of 
the animal's exposure, place where the exposure occurred, and 
the level of assurance of exposure. A clinical history is also 
obtained whenever possible and includes clinical signs and 
their severity, clinical chemistry alterations, pathological 
findings, and the animal's response to therapy. The clinical 
syndrome is also characterized by the time between the 
exposure and the onset of clinical signs. The duration of the 
clinical syndrome is recorded. 
On the basis of clinical, temporal, and exposure histories, 
IAPIC veterinarians categorize each call into one of several 
subcategories including: "toxicosis," suspected toxicosis," 
"doubtful toxicosis," "exposure," or "other situation" (syndrome 
due to a nontoxicologic cause). The IAPIC veterinarians will 
base these decisions on expected clinical signs from available 
literature, on temporal and dosage considerations, and 
previous experience with the agent in question. A case is 
defined as an "exposure" if clinical signs are not present at the 
time of the initial call. Clinical illness believed to be due to 
etiologies other than a known or suspected toxicant (e.g., 
infection, foreign body) is assessed as "other situation." If the 
animal has clinical signs at the time of the call, or if the 
animal subsequently develops clinical signs, a "toxicosis," 
"suspected toxicosis," or "doubtful toxicosis" assessment is 
used. For a case to be assessed as a "toxicosis" all temporal, 
clinical, and exposure data must be consistent with the 
expected syndrome. When the syndrome described is 
characteristic for a given agent but some data cannot be 
obtained, the case generally is assessed as a "suspected 
toxicosis." Assessment as a "toxicosis" or "suspected toxicosis" 
generally is unconfirmed by analytical methodologies. 
B.  Aminophylline Treatment Study 
The experimental protocol was reviewed and accepted for 
animal use and welfare by the Laboratory Animal Use 
Committee of the University of Illinois.   Rats were serially 
monitored with neurologic and physical examinations for 2 
hours following dosing. The rats were then monitored at 2-
hour intervals until euthanasia was performed. Euthanasia 
with an intraperitoneal overdose of pentobarbital was 
performed if an animal displayed severe or persistent seizures 
(≥15 minutes of persistent seizure activity) or if paralysis was 
present for 24 or more hours. 
Twenty adult (50-54 days, 200-225 gram), male, colony-
bred Sprague-Daley rats were evenly assigned to either a 
bromethalin and saline or a bromethalin and aminophylline 
treatment group. Rats were housed in standard plastic rodent 
cages (2 rats per cage), and were fed commercial rodent chow 
and water ad libitum. Food was withheld for 4 hours prior 
to bromethalin administration. Hexane-dissolved bromethalin 
(analytical grade bromethalin, donated by Lilly Research 
Laboratory, Greenfield, IN) was given (4.5 mg/kg) to all rats 
by gavage (total volume <0.5 ml). Aminophylline (Elkins-
Sinn, Inc., Cherry Hills NJ) was given (15 mg/kg, IM, every 
6 hours). An equivalent volume of saline was given to all 
bromethalin-no treatment (control) rats. Clinical signs, time 
to onset of signs, and survival time were recorded. Data 
concerning mean survival time were analyzed with a one-way 
ANOVA Significance was determined for all results at P ≤ 
0.05. 
RESULTS 
A.  Epidemiologic Study 
Of the 156 cases involving accidental bromethalin 
exposure received by the Illinois Animal Poison Information 
Center (IAPIC) between January 1, 1989, and December 31, 
1989, 6 (3.8%) were classified as "toxicosis," 18 (11.5%) as 
"suspected toxicosis," 17 (10.9%) as "doubtful toxicosis," and 
112 (71.8%) as "exposure." There were 145 dogs, 41 cats, 6 
pheasants, 2 goats, 1 horse, and 1 hamster reported to have 
ingested a bromethalin-based rodenticide during this time 
period. An estimate of amount was unavailable in 33% of all 
calls assessed as "exposure." An ingestion of an amount of 
bromethalin believed to be consistent with a toxicosis occurred 
in 21% of all calls assessed as "exposure." The IAPIC was 
contacted within less than 2 hours of ingestion in 63% of all 
calls assessed as "exposure." The time duration between time 
of call and ingestion was unknown for only 6% of all calls 
assessed as "exposure." No age or breed predispositions were 
noted for bromethalin-poisoned animals. Most bromethalin 
ingestions (90%) were considered accidental and 71% 
occurred in the home. During the same time period (January 
1, 1989, to December 31, 1989) the IAPIC received 26,744 
calls involving animals exposed to all products. 
Clinical signs associated with bromethalin poisoning in 15 
dogs and 13 cats were (in decreasing order): depression 
(61%), ataxia (38%), tremors (32%), paralysis (18%), 
vomiting (18%), seizures (15%), salivation (15%), and death 
(11%). Less frequently reported clinical signs included 
anorexia, diarrhea, vocalization, hyperesthesia, dyspnea, 
nystagmus, and coma. 
B.  Aminophylline Treatment Study 
One rat in the group given bromethalin and saline died 
during dosing due to apparent pulmonary aspiration of 
hexane. Clinical signs observed in rats included tremors, 
seizures, hyperactivity, ataxia, hindlimb paralysis, anorexia, 
prostration, and death. Clinical signs of bromethalin toxicosis 
developed within 1 to 3 hours postdosing. Deaths occurred 
in untreated rats within 2.5 to 7.5 hours of ingestion.   The 
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mean survival time observed in untreated rats was 4.7 hours 
(n=9). Deaths occurred in aminophylline-treated rats within 
1.5 to 25 hours of ingestion. The mean survival time 
observed in aminophylline treated rats was 8.0 hours (n=10). 
No statistically significant difference between mean survival 
times was noted (P < 0.05). 
DISCUSSION 
Bromethalin-based rodenticides, as other modern 
rodenticides, may constitute a significant hazard if improperly 
used and are ingested by nontarget species. Bromethalin-
based rodenticides were the sixth most commonly ingested 
rodenticide by animals as reported to the IAPIC in 1987 
(Trammel et al. 1989). During 1987, rodenticides with the 
greatest IAPIC call volume included brodifacoum (4061 calls), 
warfarin (488 calls), cholecalciferol (362 calls), bromadiolone 
(225 calls), diphacinone (165 calls), and bromethalin (148 
calls). Although infrequently associated with toxicosis, the 
majority of bromethalin related calls to the IAPIC during 
1989 occurred before clinical signs developed ("exposures"). 
This finding was not unexpected due to the delay (days) in 
onset of the development of toxicosis. Of these calls assessed 
as "exposure," over 20% involved animals which ingested an 
amount of bromethalin believed to potentially cause toxicosis. 
The high percentage of calls (61%) in which exposure had 
occurred less than 2 hours before contacting the IAPIC 
indicates a high potential for early therapeutic intervention. 
As with other rodenticides, bromethalin ingestion by animals 
most commonly involved dogs, occurred in the home 
environment, and was considered accidental. Therefore, 
efforts to instruct consumers and pest control applicators in 
the safe use of this rodenticide in the home (e.g., the use of 
tamper-proof bait stations) may greatly reduce inadvertent 
animal exposure. 
Clinical signs associated with bromethalin poisoning in 
dogs and cats reported to the IAPIC in this retrospective 
study included depression, ataxia, tremors, paralysis, vomiting, 
seizures, salivation, and death. Less frequently reported 
clinical signs included anorexia, diarrhea, vocalization, 
hyperesthesia, dyspnea, nystagmus, and coma. Reported 
clinical signs of bromethalin toxicosis were similar to those 
seen in a suspected case of bromethalin toxicosis in a cat and 
experimental studies in dogs (Martin and Johnson 1989, 
Dorman et al. 1990). 
Currently, treatment of bromethalin toxicosis in animals 
is primarily directed towards reducing the gastrointestinal 
absorption of bromethalin and controlling cerebral edema 
(Carson 1989). Treatment with mannitol and dexamethasone 
has been reported to reverse the development of increased 
cerebral spinal fluid pressure (CSFP) in rats which were 
sublethally dosed with bromethalin (VanLier and Cherry 
1988). The efficacy of dexamethasone and mannitol 
treatment has been studied in lethally dosed dogs (Dorman et 
al. 1990b). There was no increase in survival in dogs given 
this treatment. Repeated oral administration of superactivated 
charcoal/sorbitol (SAC/sorbitol) was associated with a delay in 
the development of clinical signs and increased survival time 
when monitored for 8 days. Therefore, activated charcoal 
administration appears to be a partially effective treatment in 
lethally-dosed dogs (Dorman et al. 1990b). 
Our limited success with treatments designed to minimize 
exposure and reduce cerebral edema stimulated a search for 
alternative treatment modalities. Previous studies have 
indicated   that   desmethylbromethalin   is   a   more   potent 
uncoupler of oxidative phosphorylation, and may contribute 
significantly to the toxicity of bromethalin. Further, the 
relative lack of toxicity observed in a species (guinea pigs), 
which is deficient in its ability to form desmethylbromethalin, 
strongly suggested a role for the microsomal activation of 
bromethalin. The use of a therapeutic agent which might 
limit the N-demethylation of bromethalin to 
desmethylbromethalin appeared rational based upon available 
toxicologic data. 
Aminophylline (theophylline ethylenediamine) was selected 
for its potential as a bromethalin antimetabolite, since it is N-
demethylated by cytochrome P450, relatively low in toxicity, 
and readily available to veterinarians. Aminophylline 
administration to rats given a uniformly lethal dose of 
bromethalin was not, however, effective in prolonging rat 
survival. Bromethalin administration did produce the 
previously described toxic syndrome in all rats regardless of 
treatment. Although aminophylline administration was not 
associated with a statistically significant increase in survival 
time, its administration was associated with almost a doubling 
of mean survival time. Whether aminophylline administration 
would be effective in modifying the more commonly observed 
delayed syndrome characterized by hindlimb paralysis and 
central nervous system depression associated with the ingestion 
of smaller bromethalin doses (<LD50) is not known. Further 
studies with aminophylline or other similar drugs using lower 
bromethalin doses may identify a suitable treatment for this 
bromethalin-induced toxic syndrome. Based upon our current 
knowledge of bromethalin metabolism and toxicity, the use of 
antimetabolite agents like aminophylline may hold promise as 
a treatment in the future. 
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